{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:09:09Z","timestamp":1793423349138,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL149645-05"],"award-info":[{"award-number":["5T32HL149645-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>In this article, we describe current and newer TTR stabilizers, TTR silencers which include small interfering RNA agents (siRNA), antisense oligonucleotides (ASO) and CRISPR-Cas9 gene editing, and TTR depleters, which investigates the use of monoclonal antibodies to remove amyloid fibril deposits for patients with advanced disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Once thought to be a rare and fatal condition, increased recognition, improved non-invasive diagnostic tools, and the explosive development of novel therapies, has transformed the landscape of transthyretin amyloid cardiomyopathy (ATTR-CM). Advances in cardiac imaging with respect to echocardiography, cardiac magnetic resonance imaging (CMR), and radionuclide bone scintigraphy has increased the diagnosis of ATTR-CM over the last twenty years. Ongoing clinical trials are evaluating several novel therapies at several mechanistic targets in the transthyretin (TTR) amyloidogenesis cascade, including the recently published findings from the study of vutrisiran, a siRNA agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Our review provides a comprehensive summary of current and emerging therapies for ATTR-CM. While these are promising, disease-modifying treatments, reaching vulnerable populations early in the disease course should be a focus for future studies and interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-024-02172-w","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:29:22Z","timestamp":1737523762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies"],"prefix":"10.1007","volume":"27","author":[{"given":"Aditi G. M.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narotham","family":"Badrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"4","key":"2172_CR1","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/ehf2.13443","volume":"8","author":"RD Adam","year":"2021","unstructured":"Adam RD. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail. 2021;8(4):2380\u201396. https:\/\/doi.org\/10.1002\/ehf2.13443.","journal-title":"ESC Heart Fail"},{"issue":"10","key":"2172_CR2","doi-asserted-by":"publisher","first-page":"1154594","DOI":"10.3389\/fcvm.2023.1154594","volume":"10","author":"D Tomasoni","year":"2023","unstructured":"Tomasoni D. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials. Front Cardiovasc Med. 2023;10(10):1154594. https:\/\/doi.org\/10.3389\/fcvm.2023.1154594.","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"2172_CR3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/clc.23434","volume":"43","author":"C Teng","year":"2020","unstructured":"Teng C, Li P, Bae JY, Pan S, Dixon RAF, Liu Q. Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy. Clin Cardiol. 2020;43(11):1223\u201331. https:\/\/doi.org\/10.1002\/clc.23434.","journal-title":"Clin Cardiol"},{"issue":"5","key":"2172_CR4","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1097\/FJC.0000000000001115","volume":"78","author":"ZJ Tushak","year":"2021","unstructured":"Tushak ZJ, Cox SZ, Cei LF, Gwathmey KG, Shah KB. Disease-modifying treatments for transthyretin amyloidosis. J Cardiovasc Pharmacol. 2021;78(5):e641. https:\/\/doi.org\/10.1097\/FJC.0000000000001115.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"2172_CR5","doi-asserted-by":"publisher","first-page":"e002558","DOI":"10.1161\/CIRCHEARTFAILURE.115.002558","volume":"9","author":"KB Shah","year":"2016","unstructured":"Shah KB, et al. Transthyretin cardiac amyloidosis in Black Americans. Circ Heart Fail. 2016;9(6):e002558. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002558.","journal-title":"Circ Heart Fail"},{"issue":"31","key":"2172_CR6","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","volume":"44","author":"A Ioannou","year":"2023","unstructured":"Ioannou A, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023;44(31):2893\u2013907. https:\/\/doi.org\/10.1093\/eurheartj\/ehad347.","journal-title":"Eur Heart J"},{"issue":"11","key":"2172_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1097\/TP.0000000000002240","volume":"102","author":"AN Rosenbaum","year":"2018","unstructured":"Rosenbaum AN, et al. Outcomes after cardiac transplant for wild type transthyretin amyloidosis. Transplantation. 2018;102(11):1909\u201313. https:\/\/doi.org\/10.1097\/TP.0000000000002240.","journal-title":"Transplantation"},{"key":"2172_CR8","doi-asserted-by":"publisher","unstructured":"Razvi Y. Cardiac transplantation in transthyretin amyloid cardiomyopathy: outcomes from three decades of tertiary center experience. Front Cardiovasc Med. 9. https:\/\/doi.org\/10.3389\/fcvm.2022.1075806.","DOI":"10.3389\/fcvm.2022.1075806"},{"issue":"2","key":"2172_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","volume":"27","author":"M Ibrahim","year":"2022","unstructured":"Ibrahim M, et al. The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev. 2022;27(2):517\u201324. https:\/\/doi.org\/10.1007\/s10741-021-10143-4.","journal-title":"Heart Fail Rev"},{"issue":"9","key":"2172_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","volume":"26","author":"G Lohrmann","year":"2020","unstructured":"Lohrmann G, et al. Stabilization of cardiac function with diflunisal in transthyretin (ATTR) Cardiac Amyloidosis. J Card Fail. 2020;26(9):753\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2019.11.024.","journal-title":"J Card Fail"},{"issue":"6","key":"2172_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","volume":"18","author":"A Casta\u00f1o","year":"2012","unstructured":"Casta\u00f1o A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR Cardiac Amyloidosis. Congestive Heart Fail. 2012;18(6):315\u20139. https:\/\/doi.org\/10.1111\/j.1751-7133.2012.00303.x.","journal-title":"Congestive Heart Fail"},{"issue":"11","key":"2172_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"issue":"1","key":"2172_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","volume":"9","author":"SJ Shah","year":"2024","unstructured":"Shah SJ, et al. Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post Hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol. 2024;9(1):25\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2023.4147.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"2172_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2305434.","journal-title":"N Engl J Med"},{"issue":"22","key":"2172_CR15","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation. 2022;146(22):1657\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060852.","journal-title":"Circulation"},{"issue":"17","key":"2172_CR16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2300757.","journal-title":"N Engl J Med"},{"issue":"1","key":"2172_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"RD Adams","year":"2023","unstructured":"Adams RD, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1\u20139. https:\/\/doi.org\/10.1080\/13506129.2022.2091985.","journal-title":"Amyloid"},{"key":"2172_CR18","doi-asserted-by":"publisher","unstructured":"Fontana M. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2024;392. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","DOI":"10.1056\/NEJMoa2409134"},{"issue":"Supplement_2","key":"2172_CR19","doi-asserted-by":"publisher","first-page":"ehac544.1767","DOI":"10.1093\/eurheartj\/ehac544.1767","volume":"43","author":"M Fontana","year":"2022","unstructured":"Fontana M, et al. NNC6019\u20130001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial. Eur Heart J. 2022;43(Supplement_2):ehac544.1767. https:\/\/doi.org\/10.1093\/eurheartj\/ehac544.1767.","journal-title":"Eur Heart J"},{"issue":"6","key":"2172_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454.","journal-title":"N Engl J Med"},{"issue":"9","key":"2172_CR21","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD, et al. A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Reports. 2018;22(9):2227\u201335. https:\/\/doi.org\/10.1016\/j.celrep.2018.02.014.","journal-title":"Cell Reports"},{"issue":"4","key":"2172_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/13506120600960882","volume":"13","author":"Y Sekijima","year":"2006","unstructured":"Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13(4):236\u201349. https:\/\/doi.org\/10.1080\/13506120600960882.","journal-title":"Amyloid"},{"issue":"1","key":"2172_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/13506129.2020.1808783","volume":"28","author":"LT Nelson","year":"2021","unstructured":"Nelson LT, Paxman RJ, Xu J, Webb B, Powers ET, Kelly JW. Blinded potency comparison of transthyretin kinetic stabilizers by subunit exchange in human plasma. Amyloid. 2021;28(1):24\u20139. https:\/\/doi.org\/10.1080\/13506129.2020.1808783.","journal-title":"Amyloid"},{"issue":"2","key":"2172_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/13506129.2021.2000388","volume":"29","author":"OK Siddiqi","year":"2022","unstructured":"Siddiqi OK, et al. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid. 2022;29(2):71\u20138. https:\/\/doi.org\/10.1080\/13506129.2021.2000388.","journal-title":"Amyloid"},{"issue":"2","key":"2172_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy T. Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277\u201385. https:\/\/doi.org\/10.1002\/ejhf.2027.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2172_CR26","doi-asserted-by":"publisher","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008193.","journal-title":"Circ Heart Fail"},{"issue":"7","key":"2172_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/cpdd.789","volume":"9","author":"PA Lockwood","year":"2020","unstructured":"Lockwood PA, et al. The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 \u00d7 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9(7):849\u201354. https:\/\/doi.org\/10.1002\/cpdd.789.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"2172_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","volume":"6","author":"BW Sperry","year":"2024","unstructured":"Sperry BW, Sultan MB, Gundapaneni B, Tai SS, Witteles RM. Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT. JACC: CardioOncol. 2024;6(2):300\u20136. https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.007.","journal-title":"JACC: CardioOncol"},{"issue":"1","key":"2172_CR29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jchf.2023.08.032","volume":"12","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P. Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study. JACC Heart Fail. 2024;12(1):150\u201360. https:\/\/doi.org\/10.1016\/j.jchf.2023.08.032.","journal-title":"\u00a0JACC Heart Fail"},{"key":"2172_CR30","doi-asserted-by":"publisher","unstructured":"Dobner S. Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy. ESC Heart Failure. 2024;11:2759\u201368.\u00a0https:\/\/doi.org\/10.1002\/ehf2.14815","DOI":"10.1002\/ehf2.14815"},{"issue":"9","key":"2172_CR31","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/ejhf.3330","volume":"26","author":"B Drachman","year":"2024","unstructured":"Drachman B, Damy T, Hanna M, Wang R, Angeli FS, Garcia-Pavia P. Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction. Eur J Heart Fail. 2024;26(9):2038\u201346. https:\/\/doi.org\/10.1002\/ejhf.3330.","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"2172_CR32","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","volume":"110","author":"SC Penchala","year":"2013","unstructured":"Penchala SC, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci. 2013;110(24):9992\u20137. https:\/\/doi.org\/10.1073\/pnas.1300761110.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2172_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.cardfail.2023.10.251","volume":"30","author":"A Masri","year":"2024","unstructured":"Masri A. Long-term safety and tolerability of Acoramidis (AG10) in symptomatic transthyretin amyloid cardiomyopathy: 4-year update from an ongoing, phase 2, open-label extension study. J Card Fail. 2024;30(1):221. https:\/\/doi.org\/10.1016\/j.cardfail.2023.10.251.","journal-title":"J Card Fail"},{"issue":"4","key":"2172_CR34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mds.23517","volume":"26","author":"R Stowe","year":"2011","unstructured":"Stowe R. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson\u2019s disease. Mov Disord. 2011;26(4):587\u201398. https:\/\/doi.org\/10.1002\/mds.23517.","journal-title":"Mov Disord"},{"issue":"1","key":"2172_CR35","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1038\/ncomms10787","volume":"7","author":"R Sant\u2019Anna","year":"2016","unstructured":"Sant\u2019Anna R. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun. 2016;7(1):10787. https:\/\/doi.org\/10.1038\/ncomms10787.","journal-title":"Nat Commun"},{"issue":"2","key":"2172_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","volume":"26","author":"J Gamez","year":"2019","unstructured":"Gamez J, et al. Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Amyloid. 2019;26(2):74\u201384. https:\/\/doi.org\/10.1080\/13506129.2019.1597702.","journal-title":"Amyloid"},{"issue":"1","key":"2172_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana M, et al. Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC: Cardiovasc Imaging. 2021;14(1):189\u201399. https:\/\/doi.org\/10.1016\/j.jcmg.2020.07.043.","journal-title":"JACC: Cardiovasc Imaging"},{"key":"2172_CR38","unstructured":"Food and Drug Administration (FDA). FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease. 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-its-kind-targeted-rna-based-therapy-treat-rare-disease. Accessed 15 July 2024."},{"issue":"3","key":"2172_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","volume":"34","author":"DP Judge","year":"2020","unstructured":"Judge DP, et al. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020;34(3):357\u201370. https:\/\/doi.org\/10.1007\/s10557-019-06919-4.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"2172_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/nat.2019.0796","volume":"30","author":"JE Sutherland","year":"2020","unstructured":"Sutherland JE, Hettinger JL, Chan A, Gilbert J, Warner GL, Davis WP. Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. Nucleic Acid Ther. 2020;30(1):33\u201349. https:\/\/doi.org\/10.1089\/nat.2019.0796.","journal-title":"Nucleic Acid Ther"},{"issue":"17","key":"2172_CR41","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1001\/archinte.166.17.1805","volume":"166","author":"KB Shah","year":"2006","unstructured":"Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166(17):1805\u201313. https:\/\/doi.org\/10.1001\/archinte.166.17.1805.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2172_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793.","journal-title":"N Engl J Med"},{"issue":"8","key":"2172_CR43","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/ene.14285","volume":"27","author":"TH Brannagan","year":"2020","unstructured":"Brannagan TH, et al. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol. 2020;27(8):1374\u201381. https:\/\/doi.org\/10.1111\/ene.14285.","journal-title":"Eur J Neurol"},{"issue":"12","key":"2172_CR44","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1007\/s00415-022-11276-8","volume":"269","author":"TH Brannagan","year":"2022","unstructured":"Brannagan TH. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. J Neurol. 2022;269(12):6416\u201327. https:\/\/doi.org\/10.1007\/s00415-022-11276-8.","journal-title":"J Neurol"},{"key":"2172_CR45","unstructured":"Food and Drug Administration (FDA). Drug Trial Snapshot: TEGSEDI. 2018. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trial-snapshot-tegsedi. Accessed 15 July 2024."},{"issue":"1","key":"2172_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid. 2020;27(1):52\u20138. https:\/\/doi.org\/10.1080\/13506129.2019.1685487.","journal-title":"Amyloid"},{"issue":"15","key":"2172_CR47","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448\u201358. https:\/\/doi.org\/10.1001\/jama.2023.18688.","journal-title":"JAMA"},{"key":"2172_CR48","unstructured":"Food and Drug Administration (FDA). Drug Trial Snapshot: TEGSEDI. 2022. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=827521. Accessed 15 July 2024."},{"key":"2172_CR49","unstructured":"Taubel J et al. Activity of follow-on dosing for an investigational in vivo CRISPR-Based Lipid Nanoparticle Therapy in Transthyretin Amyloidosis. 2024. https:\/\/www.intelliatx.com\/wp-content\/uploads\/Intellia_Follow_On-Dosing_PNS-2024_06.25.24.pdf. Accessed 15 July 2024."},{"issue":"3","key":"2172_CR50","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacbts.2019.02.002","volume":"4","author":"KW Zhang","year":"2019","unstructured":"Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis. JACC: Basic Transl Sci. 2019;4(3):438\u201348. https:\/\/doi.org\/10.1016\/j.jacbts.2019.02.002.","journal-title":"JACC: Basic Transl Sci"},{"key":"2172_CR51","unstructured":"Suhr O. PRX004, the first investigational anti-amyloid immunotherapy for the Treatment of ATTR amyloidosis: 9-month results from a phase 1 long-term extension study. 2020. https:\/\/s201.q4cdn.com\/351053094\/files\/doc_presentations\/2020\/12\/1\/PRX004-Phase-1-results-(PDF)-12.8.2020%5b3%5d.pdf. Accessed 17 Aug 2024."},{"issue":"1","key":"2172_CR52","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","volume":"12","author":"A Michalon","year":"2021","unstructured":"Michalon A. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021;12(1):3142. https:\/\/doi.org\/10.1038\/s41467-021-23274-x.","journal-title":"Nat Commun"},{"issue":"3","key":"2172_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P, et al. Phase 1 Trial of Antibody NI006 for depletion of cardiac transthyretin Amyloid. N Engl J Med. 2023;389(3):239\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2303765.","journal-title":"N Engl J Med"},{"key":"2172_CR54","unstructured":"Wall, J et. al. Preclinical characterization of AT-02, a pan-amyloid-binding immunoglobulin-peptide fusion protein capable of enhancing phagocytosis and facilitating reduction of amyloid. International Society of Amyloidosis Annual Meeting. 2022. https:\/\/gsm.utmck.edu\/research\/ACTP\/ACTP_ISA%202022%20Materials\/Wall-2_ISA%202022.pdf. Accessed 17 Aug 2024."},{"key":"2172_CR55","doi-asserted-by":"crossref","unstructured":"Wall J, et al. Characterization of the peptide-antibody fusion AT-02. International Society of Amyloidosis Annual Meeting. 2024. https:\/\/attralus.com\/posters-and-publications\/characterization-of-the-peptide-antibody-fusion-at-02-studies-to-support-its-use-as-an-immunotherapy-in-patients-with-amyloidosis. Accessed 17 Aug 2024.","DOI":"10.26226\/m.65f9bf8ae6f73964e1d4efba"},{"issue":"2","key":"2172_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1096\/fj.05-4509com","volume":"20","author":"I Cardoso","year":"2006","unstructured":"Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006;20(2):234\u20139. https:\/\/doi.org\/10.1096\/fj.05-4509com.","journal-title":"FASEB J"},{"issue":"9","key":"2172_CR57","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbadis.2008.05.005","volume":"1782","author":"B Macedo","year":"2008","unstructured":"Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochimica et Biophysica Acta (BBA) - Mol Basis Dis. 2008;1782(9):517\u201322. https:\/\/doi.org\/10.1016\/j.bbadis.2008.05.005.","journal-title":"Biochimica et Biophysica Acta (BBA) - Mol Basis Dis"},{"key":"2172_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1479-5876-8-74","volume":"8","author":"I Cardoso","year":"2010","unstructured":"Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined Doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74. https:\/\/doi.org\/10.1186\/1479-5876-8-74.","journal-title":"J Transl Med"},{"issue":"Suppl 1","key":"2172_CR59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/13506129.2012.678508","volume":"19","author":"L Obici","year":"2012","unstructured":"Obici L, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19(Suppl 1):34\u20136. https:\/\/doi.org\/10.3109\/13506129.2012.678508.","journal-title":"Amyloid"},{"issue":"3","key":"2172_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","volume":"25","author":"E Karlstedt","year":"2019","unstructured":"Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM. Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis. J Card Fail. 2019;25(3):147\u201353. https:\/\/doi.org\/10.1016\/j.cardfail.2019.01.006.","journal-title":"J Card Fail"},{"issue":"1","key":"2172_CR61","doi-asserted-by":"publisher","first-page":"26623","DOI":"10.1038\/srep26623","volume":"6","author":"N Ferreira","year":"2016","unstructured":"Ferreira N, Gon\u00e7alves NP, Saraiva MJ, Almeida MR. Curcumin: a multi-target disease-modifying agent for late-stage transthyretin amyloidosis. Sci Rep. 2016;6(1):26623. https:\/\/doi.org\/10.1038\/srep26623.","journal-title":"Sci Rep"},{"issue":"10","key":"2172_CR62","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","volume":"101","author":"AV Kristen","year":"2012","unstructured":"Kristen AV. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012;101(10):805\u201313. https:\/\/doi.org\/10.1007\/s00392-012-0463-z.","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"2172_CR63","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11739-018-1887-x","volume":"13","author":"F Cappelli","year":"2018","unstructured":"Cappelli F, et al. Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study. Intern Emerg Med. 2018;13(6):873\u201380. https:\/\/doi.org\/10.1007\/s11739-018-1887-x.","journal-title":"Intern Emerg Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02172-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:56:41Z","timestamp":1772096201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02172-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2172"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02172-w","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"7 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with\u00a0Ethical Standards"}},{"value":"KBS is on a medical advisory board for Bridgebio and Ionis; he is the PI for clinical trials funded by Bridgebio, Ionis, AstraZeneca\/Alexion, and Intellia. The other authors declare that the research was conducted in the absence of commercial or financial relationships that may be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"33"}}